Foghorn develops cancer drug candidates that target the chromatin regulatory system, which controls how genes are turned on and off. FHTX reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Prices, price targets and earnings estimates for FHTX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in FHTX in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FHTX is in one of them and how their past FHTX trades turned out.
Foghorn is a biotechnology company that develops drug candidates for cancer by targeting the chromatin regulatory system, the set of cellular components that control whether genes are switched on or off. Its lead candidate, FHD-909, is an oral medicine that blocks SMARCA2 and is being developed with the pharmaceutical company Eli Lilly. The company's end users are patients with cancer, and it is based in Cambridge, Massachusetts. It uses a proprietary platform called Gene Traffic Control to identify and test new drug targets.
